Late-stage osteoporosis drugs illustrate challenges in the field.
Alisa
A
Opar
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D000069448:Denosumab; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D053245:RANK Ligand / Q000008:administration & dosage; D013997:Time Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D053245:RANK Ligand; D000069448:Denosumab